AMB304 / Aimed Bio - LARVOL DELTA

AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP) (AACR 2025) - "Furthermore, elevated expression of the target is associated with resistance to anti-tumor drugs, such as EGFR TKIs (e.g., Gefitinib) and trastuzumab, via signaling. This study demonstrates that AMB304 is potent ADC with significant anticancer efficacy and an excellent safety profile. Moreover, its superior stability in plasma enhances its potential for clinical treatment. Therefore, AMB304 could be developed as a targeted therapy for advanced solid tumors with high target expression."

ADC • Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Aimd Bio, ADC Candidate AMB304 Selected for ’National New Drug Development Project’ [Google translation] (BioTimes) - "Aimed Bio announced on the 19th that its antibody-drug conjugate (ADC) candidate substance 'AMB304' was selected as a national new drug development project. With this project selection, Aimed Bio will receive support for the non-clinical stage development of AMB304 for the next two years....AMB304 is an ADC currently under development targeting solid cancers such as colon cancer and non-small cell lung cancer, and has recently demonstrated excellent tumor suppression effects and safety profiles in preclinical evaluations. Based on this, Aimed Bio plans to submit a phase 1 clinical trial plan (IND) to the US FDA and the Ministry of Food and Drug Safety within 2026."

Financing • IND • New trial • Colon Cancer • Colorectal Cancer • Non Small Cell Lung Cancer